Guardant Health, a leading precision oncology company, acquired Bellwether Bio, a privately held company focused on improving oncology patient care through their pioneering research into the epigenomic content of cell free DNA. Financial terms were not disclosed. “We are excited to welcome the Bellwether team and believe they will enhance our product pipeline as we seek to expand precision oncology to earlier stages of disease,” said Guardant Health Co-Founder and President AmirAli Talasaz, PhD. “Our early research has shown the strong potential impact of incorporating biologically-relevant epigenomic information on the clinical performance of blood tests for early stage cancer detection.”